US FDA Reports Shortage of Multi-Vitamin Infusion Due to Manufacturing Delays

Strategic Insights -

The United States Government, through the Food and Drug Administration, has issued a report citing a shortage of Multi-Vitamin Infusion (MVI) products, affecting both adult and pediatric patients. The shortage stems from manufacturing delays, specifically related to the transfer of manufacturing sites. The shortage affects various presentations of MVI, including vials and parenteral nutrition solutions. Healthcare professionals and patients are advised to contact wholesalers for available inventory.

Key Takeaways:

  • The US FDA has reported a shortage of Multi-Vitamin Infusion (MVI) products, including adult and pediatric formulations.
  • The shortage is attributed to manufacturing delays, specifically related to the transfer of manufacturing sites.
  • The affected presentations include vials, parenteral nutrition solutions, and other formulations.
  • Baxter Healthcare and Hospira, Inc. are the manufacturers experiencing manufacturing delays.
  • Healthcare professionals and patients are advised to contact wholesalers for available inventory.
  • The shortage affects specific National Drug Codes (NDC), including 61703-423-81, 61703-423-83, 61703-422-81, 61703-422-82, and 61703-422-83.
  • The shortage is assessed to have a significant impact on patients relying on these products for therapeutic purposes.

Statistics:

  • The shortage affects various presentations of MVI products, including vials and parenteral nutrition solutions.
  • The involved manufacturers, Baxter Healthcare and Hospira, Inc., are experiencing manufacturing delays.
  • The affected products include Multi-Vitamin Infusion Adult; MVI Adult; MVI Pediatric; and other formulations.
  • The reporting date for the shortage is not specified, as it is marked as "No date available."
  • The shortage is attributed to manufacturing site transfer delays.

Sources:

  • "Shortages and Discontinuations Report: Multi-Vitamin Infusion (Adult and Pediatric)." US FDA, no date available.